Poll Results

How will hospital and insurance plan price transparency impact patient costs?

Patients won’t notice: 40%

No impact: 20%

Increase patient costs: 20%

Decrease patient costs: 20%

What change do you most expect to see in the 340B program in the next year?

Reduced drug sales at 340B prices: 60%

Legislative changes to 340B program: 20%

HRSA lawsuit challenging 340B sales limitations by manufacturers: 20%

Shifting drug sales to 340B supportive manufacturers: 0%

Many industry conferences have been cancelled or shifted online due to COVID-19. How are you staying connected to industry colleagues?

Scheduling regular calls or online meetings: 54.5%

Participating in virtual conferences: 9.1%

Social media: 9.1%

All of the above: 27.3%

None of the above: 0%

Would you be willing to participate in a Phase 3 trial of a potential Covid-19 vaccine?

Yes: 71%

No: 29%

COVID-19 testing by community pharmacists will likely help pave the way for pharmacy provider status under Medicare, what is the expected time-frame?

1 year: 0%

2 years: 75%

3 years: 0%

4 years or more: 25%

Never: 0%

What percent of drug manufacturers will increase production of drug products in the US?

0%: 0%

1-10%: 14%

11-20%: 43%

21-30%: 29%

More than 30%: 14%

When do you feel that a COVID-19 vaccine will become available?

Less than 12 months: 8.3%

12 to 18 months: 66.7%

18 to 24 months: 25.0%

More than 24 months: 0%

Never: 0%

What impact will the coronavirus (COVID-19) have on the pharmaceutical supply chain due to API sourced from China?

High impact: 73%

Some impact: 18%

Low impact: 9%

No impact: 0%

With the approval of more biosimilars, how likely is the FDA to create an authorized generic pathway for BLAs?

Highly likely: 28.6%

Somewhat likely: 42.8%

Somewhat unlikely: 14.3%

Highly unlikely: 14.3%

If the proposed drug importation regulations are passed, what percent of the drug costs will be saved through products purchased under this regulation?

0%: 10%

1-10%: 90%

11-25%: 0%

>25%: 0%